LIke ThisLIke ThisLIke This

Lab Members

Principal Investigator:

Ofer Levy Ofer Levy, MD, PhD
Staff Physician & Principal Investigator, Division of Infectious Diseases  
Director, Precision Vaccines Program 

Research Associates and Fellows:

Asimenia Angelidou, Levy LabAsimenia Angelidou, MD, PhD
Clinical Fellow, Division of Neonatal-Perinatal Medicine 
Research Fellow, Division of Infectious Diseases

Dr. Angelidou obtained her MD and PhD in Immunopharmacology from the University of Athens in Greece. She completed her pediatric residency in the University of Texas Southwestern and is completing her clinical fellowship in Neonatal-Perinatal Medicine at Boston Children's Hospital. 

Dr. Angelidou completed a post-doctoral fellowship at Tufts University where she studied and extensively published on the role of mast cell activation in autism spectrum disorders under the mentorship of Dr. Theoharides. She joined the Levy Lab in July 2015 with an interest in neonatal innate immunity and vaccinology. Her main project focuses on characterization of vaccine-induced primary and trained innate immune activation in newborns. Trained immunity alludes to previously activated innate immunity exhibiting altered responses to subsequent stimuli. This mechanism could mediate heterologous effects of live attenuated vaccines, such as Bacille Calmette-Guérin (BCG), whereby a vaccine against one pathogen may also protect against others. This work can provide fundamental insights into the mechanisms by which common licensed neonatal vaccines protect in early life and can inform future early life vaccine development. 

Joann Arce, PhD
Research Fellow, Division of Infectious Diseases

Francesco Borriello, MD
Research Fellow, Division of Infectious Diseases

David Dowling, PhD
Project Manager, Adjuvant Discovery Program, Division of Infectious Diseases
Research Fellow in Pediatrics, Harvard Medical School

Carlo Pietrasanta, MD
Research Fellow, Division of Infectious Diseases

Guzman Sanchez-Schmitz, MSc, PhD
Co-PI & Research Associate, Division of Infectious Diseases
Research Associate, Harvard Medical School

Annette Scheid Precision Vaccines Program Annette Scheid, MD
Attending Neonatologist at Brigham and Women’s Hospital
Staff Scientist, Division of Infectious Diseases Boston Children’s Hospital

Dr. Scheid's current research interests are based on the hypothesis that accurate modeling of preterm immune responses to licensed vaccines tested alone or together with novel adjuvants will identify vaccine formulations capable of inducing robust preterm immune responses, thereby informing targeted preterm vaccine development. She is pursuing this hypothesis by characterizing preterm immune responses to licensed vaccines in relation to those of full-term newborns and adults and by determining whether vaccine efficacy towards preterm immune cells can be enhanced by combining vaccines or by adding an adjuvant or a live-attenuated vaccine such as BCG.

Simon van Haren, Levy LabSimon van Haren, PhD
Research Fellow, Division of Infectious Diseases 

Dr. van Haren obtained his Ph.D at Utrecht University in The Netherlands, where he conducted immunological and biochemical research regarding the formation of Factor VIII-neutralizing antibodies in patients with hemophilia A. His research project was focused on the mechanism of endocytosis of Factor VIII by human dendritic cells, the presentation of antigenic peptides on MHC class II and the identification of antigen-specific CD4+ T cells. During his postdoctoral fellowship in the lab of Dr. Levy, his research has focused on characterizing age-specific immune responses to vaccine adjuvants. He has modeled the immune systems of newborns, 6-month old infants, adults and elderly individuals in different in vitro settings, such as whole blood, monocytes, monocyte-derived DCs, B-and T-cells and a microphysiological tissue construct. Supported by an Early Career Award from the Thrasher Research Fund, he initiated a project that aims to identify combinations of Toll-like receptor (TLR) and C-type lectin receptor (CLR) agonists that could overcome the classical impairment in Th1-polarization seen in newborns. This study has identified novel age-dependent synergy between specific TLR and CLR agonist combinations, which are currently under evaluation for their ability to enhance early life immunity against Respiratory Syncytial Virus (RSV).

Research Assistants:

Spencer Brightman, BA
Research Technician, Division of Infectious Diseases

Andrew Greene, BA
Research Assistant I, Division of Infectious Diseases

Mark Liu, BA
Research Assistant I, Division of Infectious Diseases

Sweta Joshi, MSc, PhD
Research Assistant II, Division of Infectious Diseases


Diana Vo, BA
Program Coordinator, Division of Infectious Diseases

LIke ThisLIke ThisLIke This